{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:28:52Z","timestamp":1762522132580},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401964"],"award-info":[{"award-number":["81401964"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Government Foundation for Youth Natural Sciences","award":["20171BAB215042"],"award-info":[{"award-number":["20171BAB215042"]}]},{"DOI":"10.13039\/501100009102","name":"Jiangxi Provincial Department of Education","doi-asserted-by":"publisher","award":["GJJ170154"],"award-info":[{"award-number":["GJJ170154"]}],"id":[{"id":"10.13039\/501100009102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.cca.2018.03.042","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T12:32:12Z","timestamp":1522499532000},"page":"172-177","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Advances in biomarkers for dermatomyositis"],"prefix":"10.1016","volume":"482","author":[{"given":"Wei-ming","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.cca.2018.03.042_bb0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"issue":"5","key":"10.1016\/j.cca.2018.03.042_bb0020","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161436","article-title":"HMGB1 may be a biomarker for predicting the outcome in patients with polymyositis\/dermatomyositis with interstitial lung disease","volume":"11","author":"Shu","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.cca.2018.03.042_bb0035","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.cca.2018.03.042_bb0040","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.cca.2018.03.042_bb0050","first-page":"1627","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0055","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0060","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/1346-8138.14092","article-title":"Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis","volume":"45","author":"Li","year":"2017","journal-title":"J. Dermatol."},{"issue":"9","key":"10.1016\/j.cca.2018.03.042_bb0070","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology"},{"issue":"16","key":"10.1016\/j.cca.2018.03.042_bb0075","doi-asserted-by":"crossref","first-page":"26552","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.cca.2018.03.042_bb0080","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.cca.2018.03.042_bb0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/atm.2017.03.94","article-title":"MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis","volume":"5","author":"Sontheimer","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"2","key":"10.1016\/j.cca.2018.03.042_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-016-1704-1","article-title":"Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets","volume":"309","author":"Merlo","year":"2017","journal-title":"Dermatol. Res."},{"issue":"11","key":"10.1016\/j.cca.2018.03.042_bb0100","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0105","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.cca.2018.03.042_bb0110","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis","volume":"56","author":"Betteridge","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0115","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JND-140054","article-title":"Diagnostic utility of auto-antibodies in inflammatory muscle diseases","volume":"2","author":"Allenbach","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cca.2018.03.042_bb0135","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"Dermatol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"U.K. Juvenile Dermatomyositis Research Group, Clinical associations of autoantibodies to a p155\/140\u202fkDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cca.2018.03.042_bb0160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0165","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.23325","article-title":"Association of Anti-Transcription Intermediary Factor 1\u03b3 Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis","volume":"70","author":"Venalis","year":"2018","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0170","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cca.2018.03.042_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J. Autoimmun."},{"issue":"5","key":"10.1016\/j.cca.2018.03.042_bb0180","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.cca.2018.03.042_bb0185","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"U.K. Juvenile Dermatomyositis Research Group, Ireland, Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0190","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0195","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.arcped.2015.09.007","article-title":"Juvenile dermatomyositis and new autoantibodies: cases and review","volume":"22","author":"Guarella","year":"2015","journal-title":"Arch. Pediatr."},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0200","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cca.2018.03.042_bb0205","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and Cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cca.2018.03.042_bb0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.rdc.2011.01.002","article-title":"Polymyositis and dermatomyositis: pathophysiology","volume":"37","author":"Nagaraju","year":"2011","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"11","key":"10.1016\/j.cca.2018.03.042_bb0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-015-0543-y","article-title":"Immunological biomarkers in dermatomyositis","volume":"17","author":"Olazagasti","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"issue":"10","key":"10.1016\/j.cca.2018.03.042_bb0220","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.autrev.2017.07.021","article-title":"Using multi-omics methods to understand dermatomyositis\/polymyositis","volume":"16","author":"Gao","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3899\/jrheum.160293","article-title":"Gene expression profiling in blood and affected muscle tissues reveals differential activation pathways in patients with new-onset juvenile and adult dermatomyositis","volume":"44","author":"Lopez De Padilla","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cca.2018.03.042_bb0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12969-015-0048-2","article-title":"Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels","volume":"13","author":"Wakiguchi","year":"2015","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"10","key":"10.1016\/j.cca.2018.03.042_bb0235","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/1346-8138.13887","article-title":"Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: the relation between the disease activity and the serum interleukin-6 level","volume":"44","author":"Yasuda","year":"2017","journal-title":"J. Dermatol."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0240","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/03009742.2014.956141","article-title":"Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies","volume":"44","author":"Notarnicola","year":"2015","journal-title":"Scand. J. Rheumatol."},{"issue":"3\u20134","key":"10.1016\/j.cca.2018.03.042_bb0245","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000452563","article-title":"MiR-146a regulates inflammatory infiltration by macrophages in polymyositis\/dermatomyositis by targeting TRAF6 and affecting IL-17\/ICAM-1 pathway","volume":"40","author":"Yin","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.cca.2018.03.042_bb0250","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/keq196","article-title":"Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.cca.2018.03.042_bb0255","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s10067-016-3347-1","article-title":"The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis","volume":"35","author":"Yin","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0260","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41598-017-01685-5","article-title":"Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study","volume":"7","author":"Oda","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0265","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","year":"2014","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.cca.2018.03.042_bb0270","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3899\/jrheum.141474","article-title":"MicroRNA-10a regulation of proinflammatory mediators: an important component of untreated juvenile dermatomyositis","volume":"43","author":"Xu","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cca.2018.03.042_bb0280","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/345347","article-title":"Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0285","first-page":"17","article-title":"Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity","volume":"34","author":"Misunova","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0290","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.cca.2018.03.042_bb0295","first-page":"13","article-title":"Accurate use of neutrophil\/lymphocyte ratio from the perspective of laboratory experts","volume":"10","author":"Sertoglu","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0300","first-page":"359","article-title":"Accurate use of neutrophil\/lymphocyte ratio in patients with age-related macular degeneration","volume":"24","author":"Ozgonul","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.cca.2018.03.042_bb0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cca.2016.12.007","article-title":"Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis","volume":"465","author":"Yang","year":"2017","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir. Investig."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/crj.12341","article-title":"Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients","volume":"11","author":"Hu","year":"2017","journal-title":"Clin. Respir. J."},{"issue":"6","key":"10.1016\/j.cca.2018.03.042_bb0320","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/imj.12754","article-title":"Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study","volume":"45","author":"Chen","year":"2015","journal-title":"Intern. Med. J."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0325","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/14397595.2016.1231102","article-title":"Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis","volume":"27","author":"Sato","year":"2017","journal-title":"Mod. Rheumatol."},{"issue":"5","key":"10.1016\/j.cca.2018.03.042_bb0330","first-page":"910","article-title":"Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjogren's syndrome: a case report","volume":"49","author":"Yu","year":"2017","journal-title":"Beijing Da Xue Xue Bao"},{"issue":"6817","key":"10.1016\/j.cca.2018.03.042_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/35051594","article-title":"Identification of the haemoglobin scavenger receptor","volume":"409","author":"Kristiansen","year":"2001","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cca.2018.03.042_bb0340","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10067-012-1972-x","article-title":"Increased serum levels of soluble CD163 in patients with scleroderma","volume":"31","author":"Shimizu","year":"2012","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.cca.2018.03.042_bb0345","first-page":"979","article-title":"Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue","volume":"42","author":"Peng","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2018.03.042_bb0350","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","article-title":"Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease","volume":"19","author":"Enomoto","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0355","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3899\/jrheum.151317","article-title":"Soluble CD163: a novel biomarker with diagnostic and therapeutic implications in autoimmune diseases","volume":"43","author":"Zhou","year":"2016","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0360","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrrheum.2011.222","article-title":"HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease","volume":"8","author":"Harris","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0365","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/annrheumdis-2012-202207","article-title":"TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis","volume":"72","author":"Zong","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0370","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.12194","article-title":"Diagnosis, pathogenesis and treatment of myositis: recent advances","volume":"175","author":"Carstens","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.cca.2018.03.042_bb0375","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"Aggarwal","year":"2016","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cca.2018.03.042_bb0380","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun."},{"issue":"3","key":"10.1016\/j.cca.2018.03.042_bb0390","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.clinbiochem.2014.11.008","article-title":"Proteomic profiling of antigens in circulating immune complexes associated with each of seven autoimmune diseases","volume":"48","author":"Ohyama","year":"2015","journal-title":"Clin. Biochem."},{"issue":"4","key":"10.1016\/j.cca.2018.03.042_bb0395","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.3892\/mmr.2016.5703","article-title":"Bioinformatics analysis of gene expression profiles of dermatomyositis","volume":"14","author":"Chen","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.cca.2018.03.042_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006604","article-title":"Beyond the MHC: a canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci","volume":"13","author":"Evans","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cca.2018.03.042_bb0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.08.004","article-title":"The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies","volume":"75","author":"Bhattarai","year":"2016","journal-title":"J. Autoimmun."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811830158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989811830158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T14:36:23Z","timestamp":1604068583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989811830158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":81,"alternative-id":["S000989811830158X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2018.03.042","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in biomarkers for dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2018.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}